Trial Description Category
E4512A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinAnaplastic Lymphoma Kinase, Lung NSCLC
A011203A RANDOMIZED PHASE II TRIAL OF TAMOXIFEN VERSUS Z-ENDOXIFEN HCL IN POSTMENOPAUSAL WOMEN WITH METASTATIC ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCERBreast
NSABP B-55/ BIG 6-13A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase Iii Study To Assess The Efficacy And Safety Of Olaparib Versus Placebo as Adjuvant Treatment In Patients With Germline Brca1/2 Mutations And High Risk Her2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment And Neoadjuvant Or Adjuvant ChemotherapyBreast
S1207Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.Breast
A221405A STUDY EVALUATING THE PREGNANCY OUTCOMES AND SAFETY OF INTERRUPTINGENDOCRINE THERAPY FOR YOUNG WOMEN WITH ENDOCRINE RESPONSIVE BREAST CANCER WHO DESIRE PREGNANCY (POSITIVE)Breast, ENDOCRINE RESPONSIVE BREAST CANCER
A011202A Randomized Trial Evaluating The Role Of Axillary Lymph Node Dissection In Breast Cancer Patients (Ct1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.Breast
NRG BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerBreast
UNC LCCC 1317Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + BevacizumabColorectal, Genotype-Directed
A081105RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)Epidermal Growth Factor Receptor (EGFR), Lung NSCLC
N1048PHASE II/III Trial Of Neoadjuvant Folfox With Selective Use Of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation For Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal ExcisionGI
UNC LCCC 1330A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckHead & Neck
E2810Randomized, Double-Blind Phase III Study Of Pazopanib Vs. Placebo In Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence Of Disease Following MetastatectomyKidney, Renal
S0931EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III StudyKidney
S1400Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung CancerLung
UNC LCCC 1210A Phase II Multi-Center Study of the Tolerability of Weekly Nab-Paclitaxel as Second Line Treatment for Elderly Patients with Advanced Lung CancerLung
A151216 - ALCHEMIST -Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Lung NSCLC
EA5142Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersLung NSCLC
GHI 14-009A study to determine the concordance of key alterations as assessed in tumor tissue and plasma from patients with non-small cell lung carcinoma (NSCLC)Lung NSCLC
EAY 131 - MATCHFor Patients with Solid Tumors and Lymphomas whose Disease has Progressed Following at Least One Line of Standard Systemic Therapy or for whom No Standard Therapy ExistsMolecular Anaylsis, Solid Tumors
S1505A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic AdenocarcinomaPancreatic, Resectable Pancreatic Adenocarcinoma
A031201Phase III Trial Of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone And Prednisone For Castration Resistant Metastatic Prostate CancerProstate
A4061070Metastatic Renal Cell Cancer Registry (MaRCC Registry)Registry, Renal
E2112A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor Positive Advanced Breast Canceradvanced breast cancer, Breast, hormone receptor positive